Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab (Keytruda). Atezolizumab (Tecentriq) and durvalumab (Imfinzi) may also be given to treat certain types of NSCLC with a ...

In an analysis of Medicare's top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

The U.S. Food and Drug Administration (FDA) has approved three immunotherapy medications to treat adults with advanced squamous cell skin cancer: Cemiplimab-rwlc improves the immune system’s ability ...

In PD-(L)1 resistant hot tumors, solnerstotug+cemiplimab showed 14% ORR, nearly 3x higher than historical PD-(L)1 rechallenge response rates Solnerstotug remains well tolerated, with no dose ...